FrancophonIA/ELRC3.0 huggingface dataset:
English: Posology
Slovenian: Pordelost
English: NA= not available
Slovenian: NP= ni podatka
English: Seronegative subjects prior to vaccination N=38 [95% CI]
Slovenian: Preiskovanci, ki so bili pred cepljenjem seronegativni n=38 [95% IZ]
English: Total enrolled subjects N=58 [95% CI]
Slovenian: Skupno vključeni preiskovanci n=58 [95% IZ]
English: Ferrets immunized with the non adjuvanted H5N1 influenza vaccine were not protected from death and showed similar lung viral loads and degree of viral shedding in the upper respiratory tract as those exhibited by ferrets immunized with the adjuvant alone.
Slovenian: Pri njih je bilo virusno breme v pljučih in izločanje virusa iz zgornjih dihal podobno kot pri belih dihurjih, ki so bili cepljeni le z adjuvansom.
English: Seronegative subjects prior to vaccination N=43 [95% CI]
Slovenian: Preiskovanci, ki so bili pred cepljenjem seronegativni n=43 [95% IZ]
English: This leaflet was last approved in {MM/YYYY}.
Slovenian: Navodilo je bilo odobreno
English: GlaxoSmithKline GmbH & Co. KG Tel: + 49 (0)89 360448701 produkt.info@gsk.com
Slovenian: KG Tel: + 49 (0)89 360448701 produkt.info@gsk.com
English: Seronegative subjects prior to vaccination N=23 [95% CI]
Slovenian: Preiskovanci, ki so bili pred cepljenjem seronegativni n=23 [95% IZ]
English: NAME OF THE MEDICINAL PRODUCT Suspension for emulsion for injection for Arepanrix Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)
Slovenian: Suspenzija za emulzijo za injiciranje za cepivo Arepanrix cepivo proti pandemski gripi (H1N1) z delci virionov, inaktivirano (z adjuvansom)
English: Total enrolled subjects N=30 [95% CI]
Slovenian: Skupno vključeni preiskovanci n=30 [95% IZ]
English: • On-going clinical studies in healthy subjects who received a single dose or two doses of an AS03-containing vaccine containing HA from H1N1v manufactured using a different process
Slovenian: potekajočih kliničnih študij pri zdravih preiskovancih, ki so dobili en odmerek ali dva odmerka cepiva z AS03 z vsebnostjo HA iz H1N1v, pridobljenega z drugačnim postopkom, kliničnih študij pri zdravih preiskovancih, ki so dobili dva odmerka cepiva z AS03 z vsebnostjo HA iz H5N1, pridobljenega z drugačnim postopkom.
English: What Arepanrix contains
Slovenian: Dodatne informacije Kaj vsebuje cepivo Arepanrix
English: Seronegative subjects prior to vaccination N=27 [95% CI]
Slovenian: Preiskovanci, ki so bili pred cepljenjem seronegativni n=27 [95% IZ]
English: Total enrolled subjects N=59 [95% CI]
Slovenian: Skupno vključeni preiskovanci n=59 [95% IZ]
English: Seronegative subjects prior to vaccination N=3 [95% CI]
Slovenian: Preiskovanci, ki so bili pred cepljenjem seronegativni n=3 [95% IZ]
English: Post dose 1 Post dose
Slovenian: Po 1. odmerku Po 1. odmerku
English: • Aching muscles, joint pain
Slovenian: • bolečine v mišicah, bolečine v sklepih
English: Total enrolled subjects N=5 [95% CI]
Slovenian: Skupno vključeni preiskovanci n=5 [95% IZ]
English: Uncommon: back pain, musculoskeletal stiffness, neck pain, muscle spasms, pain in extremity
Slovenian: Bolezni mišično-skeletnega sistema in vezivnega tkiva Zelo pogosti: bolečina v sklepih, bolečine v mišicah Občasni: bolečina v hrbtu, okorelost mišično-skeletnega sistema, bolečina v vratu, mišični krči, bolečina v okončinah
English: The other ingredients are: thiomersal, sodium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, water for injections What Arepanrix looks like and contents of the pack
Slovenian: Pomožne snovi so: tiomersal, natrijev klorid, natrijev hidrogenfosfat, kalijev dihidrogenfosfat, kalijev klorid in voda za injekcije.
English: Thiomersal
Slovenian: * hemaglutinin
English: Medicinal product subject to medical prescription.
Slovenian: Izdaja cepiva je le na recept.
English: Pain
Slovenian: NP
English: In addition to the adverse reactions reported in the clinical trials, the following have been reported during post-marketing experience with an AS03-containing vaccine containing HA from H1N1v manufactured using a different process:
Slovenian: Cepivo z AS03 z vsebnostjo HA iz H1N1v, pridobljeno z drugačnim postopkom Poleg neželenih učinkov, opisanih v kliničnih preskušanjih, so bili po pridobitvi dovoljenja za promet s cepivom z AS03 z vsebnostjo HA iz H1N1v, pridobljenega z drugačnim postopkom opisani tudi naslednji neželeni učinki:
English: • Swollen glands in the axilla
Slovenian: • otekle podpazdušne bezgavke
English: Excipients: Sodium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, water for injections
Slovenian: Pomožne snovi: natrijev klorid natrijev hidrogenfosfat kalijev dihidrogenfosfat kalijev klorid voda za injekcije
English: Split influenza virus, inactivated, containing antigen* equivalent to:
Slovenian: NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Po premešanju 1 odmerek (0,5 ml) vsebuje: inaktivirane delce virusa gripe, ki vsebujejo antigene, ki ustrezajo:
English: The following information is intended for medical or healthcare professionals only: Arepanrix consists of two containers:
Slovenian: Naslednje informacije so namenjene samo zdravstvenemu osebju:
English: In a clinical study that evaluated reactogenicity in healthy adults aged 18-60 years who received two 0.5 ml doses (21 days apart) of an AS03-containing vaccine containing HA from H1N1v manufactured using a different process, there were higher rates of most general solicited symptoms (such as fatigue, headache, arthralgia, shivering, sweating and fever) after the second dose compared to the first dose.
Slovenian: V klinični študiji, s katero so ocenili reaktogenost pri zdravih odraslih, starih od 18 do 60 let, ki so dobili dva 0,5-ml odmerka (21 dni narazen) cepiva z AS03 z vsebnostjo HA iz H1N1v, pridobljenega z drugačnim postopkom, so bili deleži večine splošnih spodbujeno poročanih simptomov (npr.
English: Timelines described in the RMP
Slovenian: Časovnica je opisana v načrtu za obvladovanje tveganja.
English: Study Q-Pan H1N1-003 (6 months-8 yrs, Dose finding,)
Slovenian: študija Q-Pan H1N1-003 (6 mesecev do 8 let, določitev odmerka) - skrajšano poročilo po 1. odmerku 1. vala uporabe (imunološki podatki, spontano in nespontano zabeleženi simptomi ter resni neželeni učinki)
English: Ear and labyrinth disorders Uncommon: vertigo
Slovenian: Ušesne bolezni, vključno z motnjami labirinta Občasni: vrtoglavica
English: After mixing, use the vaccine within 24 hours and do not store above 25°C.
Slovenian: Cepivo uporabite v 24 urah po premešanju.
English: It is available as a concentrate (4 mg/5 ml) to be used to make a solution for infusion (drip) into a vein, and as a solution for infusion (4 mg/100 ml).
Slovenian: Na voljo je kot koncentrat (4 mg/5 ml) za pripravo raztopine za infundiranje (kapalne infuzije) v veno ter kot raztopina za infundiranje (4 mg/100 ml).
English: The full EPAR for Zoledronic acid Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zoledronska kislina Teva je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: For more information about treatment with Zoledronic acid Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Zoledronska kislina Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zoledronic acid Teva on 16 August 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Zoledronska kislina Teva, veljavno po vsej Evropski uniji, izdala 16. avgusta 2012.
English: This is a summary of the European public assessment report (EPAR) for Zoledronic acid Teva.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zoledronska kislina Teva.
English: The CHMP concluded that, in accordance with EU requirements, Zoledronic acid Teva has been shown to be comparable to Zometa.
Slovenian: CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Zoledronska kislina Teva primerljivo zdravilu Zometa.
English: It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue.
Slovenian: Ta zavira delovanje osteoklastov, tj. celic v telesu, ki sodelujejo pri razgradnji kostnega tkiva.
English: This includes fractures (breaks in the bone), spinal compression (when the spinal cord is compressed by the bone), bone disorders needing radiotherapy (treatment with radiation) or surgery, and hypercalcaemia (high levels of calcium in the blood).
Slovenian: Ti zapleti so zlomi kosti, spinalna kompresija (ko hrbtenjačo stisne kost), kostna obolenja, pri katerih je potrebna radioterapija (zdravljenje z obsevanjem) ali operacija, ter hiperkalciemija (visoke ravni kalcija v krvi).
English: This means that Zoledronic acid Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Zometa.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Zometa.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid Teva.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: What measures are being taken to ensure the safe and effective use of Zoledronic acid Teva?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zoledronska kislina Teva?
English: This leads to less bone loss.
Slovenian: S tem se zmanjša izguba kostne mase.
English: Because Zoledronic acid Teva is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Zoledronska kislina Teva generično zdravilo, so koristi in tveganja enaki kot pri referenčnem zdravilu.
English: When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderate problems with their kidneys.
Slovenian: Pri uporabi za preprečevanje zapletov, povezanih z okostjem, se infundiranje lahko ponovi vsake tri do štiri tedne, bolniki pa morajo prejemati tudi dodatek kalcija in vitamina D. Pri bolnikih s kostnimi metastazami (rakom, ki se je razširil na kosti), ki imajo blage do zmerne težave z ledvicami, je priporočljiv nižji odmerek zdravila.
English: The usual dose of Zoledronic acid Teva is one infusion of 4 mg over at least 15 minutes.
Slovenian: Običajni odmerek zdravila Zoledronska kislina Teva je ena 4-miligramska infuzija, ki traja najmanj 15 minut.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zoledronic acid Teva, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: What are the benefits and risks of Zoledronic acid Teva?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Zoledronska kislina Teva?
English: The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.
Slovenian: Zmanjšanje izgube kostne mase pripomore k manjši verjetnosti zloma, kar prispeva k preprečevanju zlomov pri bolnikih z rakom in metastazami v kosteh.
English: Zoledronic acid Teva can be used to prevent bone complications in adults with advanced cancer that is affecting the bone.
Slovenian: Zdravilo Zoledronska kislina Teva se lahko uporablja za preprečevanje zapletov, povezanih z okostjem, pri odraslih z napredovalim rakom, ki vpliva na kosti.
English: Zoledronic acid Teva must only be used by a doctor who has experience in the use of this type of medicine given into a vein.
Slovenian: Zdravilo Zoledronska kislina Teva smejo uporabljati le zdravniki, ki imajo izkušnje z uporabo te vrste zdravil za intravensko uporabo.
English: Zoledronic acid Teva can also be used to treat the hypercalcaemia caused by tumours.
Slovenian: Zdravilo Zoledronska kislina Teva se lahko uporablja tudi za zdravljenje hiperkalcemije, ki jo povzročajo tumorji.
English: A risk management plan has been developed to ensure that Zoledronic acid Teva is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Zoledronska kislina Teva je bil pripravljen načrt obvladovanja tveganj.
English: Other information about Zoledronic acid Teva
Slovenian: Druge informacije o zdravilu Zoledronska kislina Teva
English: Zoledronic acid Teva is a ‘generic medicine'.
Slovenian: Zdravilo Zoledronska kislina Teva je „generično zdravilo“.
English: By preventing the breakdown of bones, Zoledronic acid Teva also helps to reduce the amount of calcium released into the blood.
Slovenian: Zdravilo Zoledronska kislina Teva s preprečevanjem razgradnje kosti pripomore tudi k znižanju ravni kalcija, ki se sprosti v kri.
English: Zoledronic acid Teva is a medicine that contains the active substance zoledronic acid.
Slovenian: Zoledronska kislina Teva je zdravilo, ki vsebuje zdravilno učinkovino zoledronska kislina.
English: The Committee recommended that Zoledronic acid Teva be given marketing authorisation.
Slovenian: Priporočil je, da se za zdravilo Zoledronska kislina Teva izda dovoljenje za promet.
English: Therefore, the CHMP's view was that, as for Zometa, the benefit outweighs the identified risk.
Slovenian: Zato je menil, da njegove koristi tako kot pri zdravilu Zometa odtehtajo znana tveganja.
English: The active substance in Zoledronic acid Teva, zoledronic acid, is a bisphosphonate.
Slovenian: Zdravilna učinkovina v zdravilu Zoledronska kislina Teva, zoledronska kislina, je difosfonat.
English: Zoledronic acid Teva zoledronic acid
Slovenian: Zoledronska kislina Teva zoledronska kislina
English: Why has Zoledronic acid Teva been approved?
Slovenian: Zakaj je bilo zdravilo Zoledronska kislina Teva odobreno?
English: No additional studies were needed as Zoledronic acid Teva is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Zometa.
Slovenian: Ker je zdravilo Zoledronska kislina Teva generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Zometa, niso bile potrebne nobene dodatne študije.
English: How has Zoledronic acid Teva been studied?
Slovenian: Kako je bilo zdravilo Zoledronska kislina Teva raziskano?
English: What is Zoledronic acid Teva?
Slovenian: Kaj je zdravilo Zoledronska kislina Teva?
English: How is Zoledronic acid Teva used?
Slovenian: Kako se zdravilo Zoledronska kislina Teva uporablja?
English: What is Zoledronic acid Teva used for?
Slovenian: Za kaj se zdravilo Zoledronska kislina Teva uporablja?
English: How does Zoledronic acid Teva work?
Slovenian: Kako zdravilo Zoledronska kislina Teva deluje?
English: EU Number
Slovenian: Številka EU Izmišljeno ime
English: Invented name Strength Pharmaceutical Form
Slovenian: Farmacevtska oblika
English: Route of Administration
Slovenian: Način uporabe zdravila
English: The majority of these reactions were mild or moderate and of short duration.
Slovenian: Reakcije so bile večinoma blage ali zmerne in kratkotrajne.
English: It is available as tablets (18 mg).
Slovenian: Na voljo je v obliki tablet (18 mg).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Selincro on 25 February 2013.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Selincro, veljavno po vsej Evropski uniji, odobrila dne 25. Februarja 2013.
English: Data on the use of Selincro from standard clinical studies are available for a period of six months to one year.
Slovenian: Podatki o uporabi zdravila Selincro iz standardnih kliničnih študij so na voljo za obdobje od šestih mesecev do enega leta.
English: Only one tablet can be taken on any given day and it should preferably be taken one to two hours before they are likely to start drinking.
Slovenian: Vzame lahko samo eno tableto katerikoli dan, po možnosti eno do dve uri pred verjetnim začetkom pitja.
English: The full EPAR for Selincro can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Selincro je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: As a guide: a bottle of wine (750 ml; 12% alcohol by volume) contains approximately 70 g alcohol and a bottle of beer (330 ml; 5% alcohol by volume) contains approximately 13 g alcohol.
Slovenian: Kot vodilo: steklenica vina (750 ml; 12 vol. % alkohola) vsebuje približno 70 g alkohola, steklenica piva (330 ml; 5 vol. % alkohola) pa vsebuje približno 13 g alkohola.
English: At the patient's initial visit to their doctor, the patient's overall health, alcohol dependence, and level of alcohol consumption (based on patient reporting) will be evaluated.
Slovenian: Ob prvem obisku bolnika pri zdravniku se ovrednoti njegovo splošno zdravstveno stanje, odvisnost od alkohola in stopnjo uživanja alkohola (na podlagi bolnikovega poročanja).
English: This is a summary of the European public assessment report (EPAR) for Selincro.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Selincro.
English: Selincro nalmefene
Slovenian: Selincro nalmefen
English: The main measures of effectiveness were the reduction in the number of heavy drinking days and the average daily alcohol consumption after six months of treatment.
Slovenian: Glavno merilo učinkovitosti je bilo zmanjšanje števila dni prekomernega pitja in povprečne količine dnevno zaužitega alkohola po šestih mesecih zdravljenja.
English: Thereafter, the patient will be asked to record his or her alcohol consumption for approximately two weeks.
Slovenian: Zatem se bolnika pozove, da približno dva tedna beleži svoje uživanje alkohola.
English: The most common side effects (seen in more than 1 patient in 10) were nausea (feeling sick), dizziness, insomnia (difficulty sleeping) and headache.
Slovenian: Najpogostejši neželeni učinki zdravila (opaženi pri več kot 1 od 10 bolnikov) so bili navzea (slabost), omotica, nespečnost (težave s spanjem) in glavobol.
English: It should only be used together with psychosocial support (counselling) and only in people who do not have physical withdrawal symptoms and who do not require immediate detoxification.
Slovenian: Uporablja se lahko samo sočasno s psihosocialno podporo (svetovanjem) in samo pri bolnikih, ki nimajo fizičnih odtegnitvenih simptomov in ne potrebujejo takojšnje detoksifikacije.
English: The effects of Selincro were first tested in experimental models before being studied in humans.
Slovenian: Učinki zdravila Selincro so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
English: The patient should take one Selincro tablet by mouth ‘as needed', which means when there is a risk that they would start drinking.
Slovenian: Bolnik mora vzeti eno tableto zdravila Selincro peroralno „po potrebi“, tj. ko obstaja tveganje, da bi bolnik začel piti alkohol.
English: For more information about treatment with Selincro, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Selincro preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Selincro was compared with placebo (a dummy treatment) in two main studies involving 1,322 men and women with alcohol dependence.
Slovenian: Zdravilo Selincro so primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh glavnih študijah, ki sta vključevali 1 322 moških in žensk z odvisnostjo od alkohola.
English: If the patient has started drinking without Selincro, a tablet should be taken as soon as possible.
Slovenian: Če je bolnik začel piti alkohol, ne da bi vzel zdravilo Selincro, mora vzeti tableto v najkrajšem možnem času.
English: The CHMP decided that Selincro's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Selincro večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: The active substance in Selincro, nalmefene, attaches to certain opioid receptors in the brain.
Slovenian: Zdravilna učinkovina v zdravilu Selincro, nalmefen, se veže na nekatere opioidne receptorje v možganih.
English: Opioid receptors play a role in addiction and, by attaching to them and modifying their activity, nalmefene helps reduce the urge to drink in people accustomed to large amounts of alcohol.
Slovenian: Opioidni receptorji imajo pomembno vlogo pri zasvojenosti, zato nalmefen, ki se veže nanje in spremeni njihovo delovanje, pomaga zmanjšati potrebo po pitju pri bolnikih, ki so navajeni uživati velike količine alkohola.
English: Selincro does not prevent the intoxicating effects of alcohol.
Slovenian: Zdravilo Selincro ne preprečuje učinkov zastrupitve z alkoholom.
English: Selincro must not be used in people who are hypersensitive (allergic) to nalmefene or any of its other ingredients.
Slovenian: Zdravila Selincro ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) nalmefen ali katero koli drugo sestavino zdravila.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Selincro.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Selincro, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: All patients also received counselling to help them reduce their drinking and keep to their treatment.
Slovenian: Vsi bolniki so bili deležni tudi svetovanja, ki naj bi jim pomagalo zmanjšati pitje alkohola in držati se zdravljenja.
English: It must also not be used in patients with severe liver or kidney impairment or a recent history of acute alcohol withdrawal syndrome (including hallucinations, seizures (fits) and tremors).
Slovenian: Prav tako ga ne smejo uporabljati bolniki s hudo okvaro jeter ali ledvic in bolniki z nedavnim akutnim sindromom odtegnitve alkohola (ki vključuje halucinacije, epileptične napade (krče) in tremor).
English: In these patients, after six months, the number of heavy drinking days a month with Selincro fell from 23 to 10 in the first study and from 23 to 11 in the second.
Slovenian: Pri teh bolnikih se je po šestih mesecih jemanja zdravila Selincro število dni prekomernega pitja na mesec v prvi študiji zmanjšalo s 23 na 10, v drugi pa s 23 na 11.
English: Treatment must also include counselling to help the patient reduce their drinking and keep to their treatment.
Slovenian: Zdravljenje mora vključevati tudi svetovanje, ki bolniku pomaga zmanjšati pitje alkohola in se držati zdravljenja.
English: Before starting treatment with Selincro, the patient is asked to record their level of alcohol consumption over a two week period.
Slovenian: Pred začetkom zdravljenja z zdravilom Selincro mora bolnik dva tedna beležiti stopnjo uživanja alkohola.